Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) Consolidated Net Income (2021 - 2025)

Historic Consolidated Net Income for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $51.4 million.

  • Krystal Biotech's Consolidated Net Income rose 1291.5% to $51.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $204.8 million, marking a year-over-year increase of 12962.93%. This contributed to the annual value of $204.8 million for FY2025, which is 12973.68% up from last year.
  • Krystal Biotech's Consolidated Net Income amounted to $51.4 million in Q4 2025, which was up 1291.5% from $79.4 million recorded in Q3 2025.
  • In the past 5 years, Krystal Biotech's Consolidated Net Income registered a high of $80.7 million during Q3 2023, and its lowest value of -$50.0 million during Q1 2022.
  • For the 5-year period, Krystal Biotech's Consolidated Net Income averaged around $4.8 million, with its median value being -$7.3 million (2021).
  • As far as peak fluctuations go, Krystal Biotech's Consolidated Net Income crashed by 21599.42% in 2022, and later surged by 373015.02% in 2025.
  • Quarter analysis of 5 years shows Krystal Biotech's Consolidated Net Income stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then surged by 423.62% to $45.5 million in 2024, then increased by 12.91% to $51.4 million in 2025.
  • Its Consolidated Net Income was $51.4 million in Q4 2025, compared to $79.4 million in Q3 2025 and $38.3 million in Q2 2025.